Skip to content

US · WAT · MEDICAL - DIAGNOSTICS & RESEARCH

Waters Corporation (WAT) intrinsic value and stock valuation

$440.45as of 2026-11-21 · Mkt cap 30.43B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Waters Corporation DCF and intrinsic value

InvestorsCraft values WAT with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from WAT’s statements →

Waters Corporation Graham Number

Graham Number: $102.26d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Milford, MA 01757 waters.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.17B+6% 5y CAGRd
20112025
Net income
$642.6M+4.3% 5y CAGRd
20112025
Free cash flow
$539.8M-2.7% 5y CAGRd
20112025
Total equity
$2.56B+61.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.17B$2.96B$2.96B$2.97B$2.79B
Operating income$893.2M$826.4M$817.7M$873.4M$821.7M
Net income$642.6M$637.8M$642.2M$707.8M$692.8M
EPSd$10.8M$10.7M$10.8M$11.7M$11.2M
Operating cash flow$652.6M$762.1M$602.8M$611.7M$747.3M
Capital expenditure-$-112.75M-$-142.48M-$-160.63M-$-183.46M-$-168.27M
Free cash flow$539.8M$619.6M$442.2M$428.2M$579M
Total assets$5.08B$4.55B$4.63B$3.28B$3.09B
Total debt$1.49B$1.7B$2.44B$1.66B$1.6B
Net debt$903.3M$1.38B$2.05B$1.18B$1.1B
Total equity$2.56B$1.83B$1.15B$504.5M$367.6M
Cash and short-term investments$587.8M$325.4M$396M$481.4M$569.3M
Income statement
20252024202320222021
Revenue$3.17B$2.96B$2.96B$2.97B$2.79B
Cost of revenue$1.34B$1.2B$1.2B$1.25B$1.16B
Gross profit$1.83B$1.76B$1.76B$1.72B$1.63B
Research and development expenses$195.2M$183M$174.9M$176.2M$168.4M
Selling, general and administrative expenses$740.3M$690.2M$736M$658M$627M
Other expenses$0.00$58.7M$32.6M$16.2M$12.3M
Operating expenses$935.5M$931.8M$943.5M$850.4M$807.6M
Cost and expenses$2.27B$2.13B$2.14B$2.1B$1.96B
Interest income$7.39M$17.4M$16.6M$11M$12.2M
Interest expense$69.6M$89.7M$98.9M$48.8M$44.9M
Depreciation and amortization$206.2M$191.8M$165.9M$130.4M$131.7M
Ebitda$1.01B$1.04B$1B$1.02B$982.8M
Operating income$893.2M$826.4M$817.7M$873.4M$821.7M
Total other income/expenses, net-$-138.34M-$-71.48M-$-81.43M-$-35.55M-$-15.51M
Income before tax$754.9M$754.9M$736.2M$837.9M$806.2M
Income tax expense$112.3M$117M$94M$130.1M$113.4M
Net income$642.6M$637.8M$642.2M$707.8M$692.8M
Weighted average shares outstanding$59.5M$59.3M$59.1M$60M$61.6M
Weighted average diluted shares outstanding$59.7M$59.6M$59.3M$60.3M$62M
Balance sheet
20252024202320222021
Cash and short-term investments$587.8M$325.4M$396M$481.4M$569.3M
Net receivables$828.8M$733.4M$702.2M$722.9M$612.7M
Inventory$572.4M$477.3M$516.2M$455.7M$356.1M
Total current assets$2.15B$1.67B$1.75B$1.76B$1.63B
Property, plant and equipment, net$722.8M$725.4M$723.7M$668.7M$632.7M
Goodwill and intangible assets$1.9B$1.86B$1.93B$657.7M$680.3M
Long-term investments$350K$0.00$0.00$0.00$0.00
Total non-current assets$2.93B$2.88B$2.87B$1.52B$1.47B
Total assets$5.08B$4.55B$4.63B$3.28B$3.09B
Accounts payable$103.8M$99.9M$84.7M$93.3M$96.8M
Short-term debt$491.1M$25.5M$77.8M$76.4M$27.9M
Deferred revenue$266.5M$250.8M$256.7M$227.9M$227.6M
Total current liabilities$1.24B$789.8M$789.6M$785.7M$680.5M
Long-term debt$1,000M$1.68B$2.36B$1.59B$1.57B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.28B$1.94B$2.69B$1.99B$2.05B
Capital lease obligations$83.6M$75.9M$86.8M$88.5M$87.5M
Total liabilities$2.52B$2.73B$3.48B$2.78B$2.73B
Common stock$1.63M$1.63M$1.63M$1.62M$1.62M
Retained earnings$10.4B$9.79B$9.15B$8.51B$7.8B
Accumulated other comprehensive income (loss)-$-125.45M-$-155.28M-$-134.12M-$-141.57M-$-111.86M
Total equity$2.56B$1.83B$1.15B$504.5M$367.6M
Total investments$350K$930K$900K$860K$68.1M
Total debt$1.49B$1.7B$2.44B$1.66B$1.6B
Net debt$903.3M$1.38B$2.05B$1.18B$1.1B
Cash flow statement
20252024202320222021
Net income$642.6M$637.8M$642.2M$707.8M$692.8M
Depreciation and amortization$206.2M$191.8M$165.9M$130.4M$131.7M
Stock-based compensation$54.1M$44.7M$36.9M$42.6M$29.9M
Change in working capital-$-233.38M-$-111.37M-$-240.26M-$-269.08M-$-107.17M
Accounts receivable-$-55.5M-$-66.24M$49.2M-$-137.87M-$-62.45M
Inventory-$-65.93M$20.9M-$-45.44M-$-101.9M-$-67.25M
Accounts payable-$-89.01M$61.6M-$-79.52M$61M$46.1M
Net cash provided by operating activities$652.6M$762.1M$602.8M$611.7M$747.3M
Investments in property, plant and equipment-$-112.75M-$-142.48M-$-160.63M-$-183.46M-$-168.27M
Acquisitions, net-$-35.05M-$-1.49M-$-1.28B-$-1.37M$7M
Net cash used for investing activities-$-152.25M-$-144.02M-$-1.44B-$-107.97M-$-231.63M
Common stock issued$20.8M$0.00$0.00$0.00$0.00
Common stock repurchased-$-14.67M-$-13.54M-$-70.28M-$-626.06M-$-648.93M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-237.21M-$-696.67M$755M-$-509.63M-$-438.27M
Net change in cash$262.5M-$-70.66M-$-85.45M-$-20.7M$64.5M
Cash at end of period$587.8M$324.4M$395.1M$480.5M$501.2M
Operating cash flow$652.6M$762.1M$602.8M$611.7M$747.3M
Capital expenditure-$-112.75M-$-142.48M-$-160.63M-$-183.46M-$-168.27M
Free cash flow$539.8M$619.6M$442.2M$428.2M$579M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Waters Corporation

        Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

        CEO
        Udit Batra
        Employees
        7.9K
        Beta
        1.20

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Waters Corporation (WAT)?

        Waters Corporation (WAT) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is WAT undervalued?

        WAT trades at a price of $440.45 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.